Summit Therapeutics Inc is a biopharmaceutical firm based in Miami, Florida, dedicated to advancing healthcare with innovative medicinal therapies. It specializes in developing treatments for challenging diseases, with a focus on immunotherapy and anti-infectives. Its leading project, Ivonescimab, is a pioneering bispecific antibody aimed at enhancing immunotherapy by targeting PD-1 and blocking angiogenesis. Additionally, Summit is working on SMT-738, a new class of precision antibiotics designed to combat multidrug-resistant infections. The company collaborates with Akeso, Inc. to bring ivonescimab to market, showcasing its commitment to addressing unmet medical needs.
After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho healthcare strategist Jared Holz reframed the sector, arguing that years of…
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA…
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that insider buys often lead…
In the past week or so, a gold and silver miner, an offshore driller, and a biotech saw some huge insider buying. These were not the only notable purchases.
The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't the only notable buy in the past week or so.
Insiders know their company the best. So, if they’re buying a good deal of shares, there’s often a reason for it. However, don’t buy a stock just because an insider is buying. …
